Ngalaba Mba Nile

N'ụwa niile gbasara nchọpụta na ọgwụgwọ nke kansa akpa ume, nchọpụta mbụ na ọgwụgwọ ziri ezi nke eriri akpa ume abụrụla ihe ndị dọkịta na-elebara anya mgbe niile. Dịka onyinyo dị oke nkọ na onyonyo akpa ume, eriri akpa ume dị iche iche n'ụdị ya, site na mbufụt na-adịghị mma ruo na mbido...GỤKWUO»

N'oge njem ịlụso ọrịa kansa ọgụ, ndị dọkịta anọwo na-achọkarị ụzọ ọgwụgwọ dị irè na nke dị nchebe karị. Ọ bụ ezie na ịwa ahụ, radiotherapy, chemotherapy, na biotherapy atọọla ntọala siri ike maka ọgwụgwọ kansa, hyperthermia - teknụzụ ọgbara ọhụrụ sitere na amamihe oge ochie -...GỤKWUO»

N'ịhụ nchọpụta ọrịa kansa, olileanya nke ndị ọrịa n'ụwa niile nwere bụ ịchọta ụzọ kachasị dị irè, dị elu, na nke kacha nta maka ọgwụgwọ. Ọ bụrụ na ị na-achọ ụlọ ọgwụ nke jikọtara ọkachamara ahụike China kachasị elu, teknụzụ kachasị ọhụrụ, na ọrụ ọkọlọtọ mba ụwa, nke a...GỤKWUO»

Mgbe gị maọbụ onye ị hụrụ n'anya chere ihu na ọrịa kansa ma nwee mmetụta nke enweghị oke ma ọ bụ enweghị olileanya mgbe ị na-achọ ọgwụgwọ n'ógbè gị, ị̀ na-eche mgbe niile: N'akụkụ nke ọzọ nke ụwa, enwere nhọrọ ọgwụgwọ ka mma, nke na-adịghị emerụ ahụ, na nke nwere olileanya karịa dị? Maka ajụjụ gbasara ọgwụgwọ kansa ọhụrụ...GỤKWUO»

Otu onye ọrịa kansa ụbụrụ nke na-anwụ anwụ, onye laghachiri azụ mgbe ọ gwọchara CAR-T ugboro 17, hụrụ etuto ahụ ya ka ọ na-apụ kpamkpam n'ime izu anọ nke natara ọgwụgwọ TIL ọhụrụ ma ọ nọgideghị na-enwe etuto ahụ ruo ihe karịrị ọnwa 20. Maka ajụjụ gbasara ọgwụgwọ kansa ọhụrụ na nnwale ahụike: Ekwentị: 4008803716 | WeChat:...GỤKWUO»

N'abalị iri na asaa nke ọnwa Nọvemba, afọ 2025, Abbisko kwupụtara ngosipụta nke arụmọrụ ogologo oge, nchekwa na nsonaazụ ndị ọrịa kọrọ site na ọmụmụ zuru ụwa ọnụ nke Phase III MENUEVER nke pimicotinib (ABSK021) na ndị ọrịa nwere tenosynovial giant cell tumor (TGCT) na Connective Tissue Oncology Society (CTOS) 2025 ...GỤKWUO»

Na Septemba 8, 2025, InnoCare Pharma kwupụtara na Health Sciences Authority (HSA) nke Singapore akwadola HIBRUKA (orelabrutinib) maka ọgwụgwọ nke ndị okenye nwere lymphoma mpaghara azụ ma ọ bụ nke na-adịghị mma (R/R MZL). Ugbu a, enwere ọtụtụ nnwale ahụike nke ọrịa ọhụrụ...GỤKWUO»

Na Ọgọst 28, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a na-atụ aro ka BL-B01D1 maka ịgba ọgwụ tinye ya na usoro nyocha mbụ. A na-eme ya maka ndị ọrịa nwere kansa nasopharyngeal na-emegharị ahụ ma ọ bụ nke metastatic bụ ndị nwere...GỤKWUO»

Na Ọgọst 21, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) enyela nyocha mbụ nke ọgwụ T cell, epcoritamab. A na-akwado nkwenye a maka ndị ọrịa toro eto nwere ọrịa lymphoma follicular relapsed ma ọ bụ refractory (FL), nke bụ nnukwu ihe dị mkpa maka...GỤKWUO»

Na Ọgọst 29, Boehringer Ingelheim's HERNEXEOS® (mkpụrụ ọgwụ zongertinib) ka akwadoro dị ka otu ọgwụgwọ site na National Medical Products Administration (NMPA) nke China maka ọgwụgwọ ndị okenye nwere ọrịa kansa akpa ume nke a na-apụghị ịgbanahụ, nke dịla elu ma ọ bụ nke na-abụghị obere mkpụrụ ndụ kansa (NSCLC) nke etuto ahụ ha nwere ...GỤKWUO»

Na Ọgọst 22, 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) enwetala nkwado na China maka ọgwụgwọ nke ndị okenye nwere hormone receptor-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, ma ọ bụ IHC 2+/in situ hybridization [ISH] negative) ara...GỤKWUO»

Na Ọgọst 2025, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) nyere ikike maka Breakthrough Therapy Nhọpụta na Ina-cel, ọgwụgwọ mkpụrụ ndụ CAR-T ọhụrụ nke CD19 duziri nke Juventas mepụtara n'onwe ya, maka ọgwụgwọ ndị ọrịa ụmụaka nwere ọrịa re...GỤKWUO»